Compare Aizon vs. Process XE

We empower pharma companies and CDMOs with the tools to scale production while addressing supply-chain bottlenecks, complex materials, and rising development costs. Leverage AI and machine-learning to predict future outcomes with the leading manufacturing cloud. Always in compliance. Collecting and integrating real-time and historic data from multiple sources in a GxP compliant manner, and turning it into actionable insight. Use artificial intelligence (AI), machine learning, and other technologies to identify patterns that could lead to deviations. Fix them before they become a problem. The Aizon platform optimizes pharma manufacturing processes by using real-time data from disparate sources and predictive models. The Aizon platform allows for GxP-compliant acquisition, storage, consumption, and auditing. Aizon works closely with international regulatory bodies in order to ensure AI algorithms are qualified.

Process XE by Sarjen Systems is a powerful Manufacturing Process Automation solution tailored for the pharmaceutical industry, serving as a full-featured Manufacturing Execution System (MES). It enhances shop floor visibility, control, and efficiency by automating key processes such as batch production, packaging, and equipment management. The platform captures real-time data in strict adherence to ALCOA+ principles and meets 21 CFR Part 11 regulatory compliance requirements. Its standout features include electronic batch records (eBMR/eBPR) for streamlined documentation, robust weighing and dispensing management systems (WDMS), and comprehensive digital logbooks to replace paper records. Process XE supports a paperless manufacturing environment, facilitating audit readiness and improving operational transparency. By providing end-to-end traceability and ensuring data integrity, it helps pharmaceutical manufacturers optimize quality and compliance. The system’s real-time monitoring and control tools enable swift decision-making on the shop floor. Sarjen Systems’ Process XE is ideal for pharma companies looking to digitize and modernize their manufacturing operations.